Eyevensys: Funding, Investors & Team (Sep 2026)
Eyevensys is a address critical unmet needs in ophthalmology by providing a much better way of delivering ophthalmic drugs that overcomes the limitations of current options, such as intravitreal injections, surgery, intravitreal implants and biodegradable formulations. All of these current options have their drawbacks, given they are invasive procedures. Eyevensys’ goal is not only to improve short and long term therapeutic outcomes, but also to enhance compliance, improve ocular bioavailability and tolerability. They plan to build a high value product pipeline by enabling sustained production of therapeutic proteins in the eye that will deliver improved clinical outcomes while reducing the burden of frequent intravitreal or systemic injections and other invasive procedures.
Eyevensys has raised $12.0M across 1 funding round on record, the most recent a Series B of $12.0M announced in Aug 2021.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Eyevensys Company Profile and Key Stats
Latest funding round on record: Aug 2021.
Eyevensys Funding Rounds
Eyevensys Founders and Leadership Team
No contact details are on record for this team yet.
Eyevensys Funding Compared to Other Biotechnology Startups
Eyevensys' latest round of $12.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Eyevensys in Biotechnology and Paris
Companies Similar to Eyevensys
Brenus Pharma is a platform that uses allogeneic techniques to create immune therapy with the goal of…
TISSIUM is a privately owned medical device company based in Paris, France that is dedicated to the rapid…
NicOx is a biopharmaceutical company that focuses on creating and selling nitric oxide-donating drugs for…
Advicenne is a specialty pharmaceutical company dedicated to improving the lives of patients who suffer from…
One Biosciences was founded in Paris, Ile-de-France, France by Magali Richard, David Schilansky, and Céline…
Inventiva Pharma is a biopharmaceutical company in the clinical stage that focuses on creating oral small…
NETRIS Pharma develops therapeutic molecules for treating cancer by targeting dependence receptors for the…
AbIONYX Pharma is a biotechnology company that is focused on providing innovative therapies for indications…
Founded in 2003, Nanobiotix is at the forefront of nanomedicine and is committed to revolutionizing patient…
Theraclion specializes in high-tech medical equipment using high-intensity focused ultrasound (HIFU). They…
Abivax, a clinical stage biotechnology company, is mobilizing the body’s natural immune machinery to treat…
AB Science was established in 2001 by a group of individuals in the medical and business fields who are…
Eyevensys Funding FAQs
What does Eyevensys do?
Eyevensys is a address critical unmet needs in ophthalmology by providing a much better way of delivering ophthalmic drugs that overcomes the limitations of current options, such as intravitreal injections, surgery, intravitreal implants and biodegradable formulations. All of these current options have their drawbacks, given they are invasive procedures. Eyevensys’ goal is not only to improve short and long term therapeutic outcomes, but also to enhance compliance, improve ocular bioavailability and tolerability. They plan to build a high value product pipeline by enabling sustained production of therapeutic proteins in the eye that will deliver improved clinical outcomes while reducing the burden of frequent intravitreal or systemic injections and other invasive procedures.
How much funding has Eyevensys raised?
Eyevensys has raised $12.0M across 1 round on record. The most recent is a Series B of $12.0M announced in Aug 2021.
When did Eyevensys last raise funding?
Eyevensys' most recent funding round on record is a Series B of $12.0M, announced in Aug 2021.
Who is the CEO of Eyevensys?
Patricia Zilliox is listed as CEO at Eyevensys.
Where is Eyevensys headquartered?
Eyevensys is based in Paris, Ile-De-France, France.
How many employees does Eyevensys have?
Eyevensys is in the 11-50 employee band.
How does Eyevensys' funding compare to other Biotechnology startups?
Eyevensys' latest round of $12.0M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's Eyevensys Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Eyevensys is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.